Mycobacterium noviomagense sp. nov.; clinical relevance evaluated in 17 patients

Ingen, Jakko van; Boeree, Martin J.; Lange, Wiel C M de; Haas, Petra E. W. de; Zanden, Adri G. M. van der; Mijs, Wouter; Rigouts, Leen; Dekhuijzen, P.N.R.; Soolingen, Dick van

doi:10.1099/ijs.0.001511-0

Cited by 18 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, new methods for identification are needed. Using additional methods for identification, the Netherlands recently described the distinction between M. noviomagense and M. xenopi , to which it is closely related [27]. M. xenopi is clinically significant in a high percentage of the patients whereas M. noviomagense has never been associated with NTM disease.…”

Section: Discussionmentioning

confidence: 99%

Inventory study of non-tuberculous mycobacteria in the European Union

et al. 2014

View full text Add to dashboard Cite

BackgroundSince non-tuberculous mycobacteria (NTM) disease is not notifiable in most European Union (EU) and European Economic Area (EEA) countries, the epidemiological situation of the >150 NTM species is largely unknown. We aimed to collect data on the frequency of NTM detection and NTM species types in EU/EEA countries.MethodsOfficially nominated national tuberculosis reference laboratories of all EU/EEA countries were asked to provide information on: laboratory routines for detection and identification of NTM, including drug sensitivity testing (DST) methods; data on the number and type of NTM species identified; coverage and completeness of the provided data on NTM; type and number of human specimens tested for NTM; and number of specimens tested for Mycobacterium tuberculosis complex and NTM. This information was summarized and the main results are described.ResultsIn total, 99 different NTM species were identified with M. avium, M. gordonae, M. xenopi , M. intracellulare, and M. fortuitum identified most frequently. Seven percent of the NTM species could not be identified. NTM was cultured from between 0.4-2.0% of the specimens (data from four countries). The laboratories use culturing methods optimised for M. tuberculosis complex. Identification is mainly carried out by a commercial line probe assay supplemented with sequencing. Most laboratories carried out DST for rapid growers and only at the explicit clinical request for slow growers.ConclusionIt is likely that the prevalence of NTM is underestimated because diagnostic procedures are not optimized specifically for NTM and isolates may not be referred to the national reference laboratory for identification. Due to the diagnostic challenges and the need to establish the clinical relevance of NTM, we recommend that countries should concentrate detection and identification in only few laboratories.

show abstract

Section: Discussionmentioning

confidence: 99%

Inventory study of non-tuberculous mycobacteria in the European Union

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Based on our re-analysis of the partial 16S rRNA gene sequence, 20 UMS (yielding 93 isolates; 52%) could be assigned to validly published species, including Mycobacterium noviomagense (UMS1; Table 1), which we described recently [9]. The remaining 85 isolates, comprising 33 UMS, were related to the M. avium complex (n = 10), M. fortuitum complex (n = 7), Mycobacterium xenopi (n = 3), Mycobacterium terrae complex (n = 4), Mycobacterium gordonae (n = 3), Mycobacterium simiae (n = 2), Mycobacterium interjectum (n = 2) or assigned to the slow or rapid growers, distantly related to established species (Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…In our previous identification of M. noviomagense, we noted that close genetic relationships with M. xenopi were associated with very different phenotypical features, drug susceptibility and clinical relevance [9]. Genetic relationships, based on a partial single target should, therefore, be interpreted with caution.…”

Section: Discussionmentioning

confidence: 98%

“…Importantly, we also recorded differences in identification results between the two hybridization assays tested. Because clinical relevance and drug susceptibility of NTM species differs, correct identification is important [3,[8][9][10][11]. Sequence-based identification is more reliable than the limited approach of reverse line blot assays, although this requires sophisticated and expensive laboratory equipment and may be most suitable for reference laboratories.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Re-analysis of 178 previously unidentifiable Mycobacterium isolates in the Netherlands in 1999–2007

Ingen

Zwaan

Enaimi

et al. 2010

Clinical Microbiology and Infection

Self Cite

View full text Add to dashboard Cite

Nontuberculous mycobacteria (NTM) that cannot be identified to the species level by reverse line blot hybridization assays and sequencing of the 16S rRNA gene comprise a challenge for reference laboratories. However, the number of 16S rRNA gene sequences added to online public databases is growing rapidly, as is the number of Mycobacterium species. Therefore, we re-analysed 178 Mycobacterium isolates with 53 previously unmatched 16S rRNA gene sequences, submitted to our national reference laboratory in 1999–2007. All sequences were again compared with the GenBank database sequences and the isolates were re-identified using two commercially available identification kits, targeting separate genetic loci. Ninety-three out of 178 isolates (52%) with 20 different 16S rRNA gene sequences could be assigned to validly published species. The two reverse line blot assays provided false identifications for three recently described species and 22 discrepancies were recorded in the identification results between the two reverse line blot assays. Identification by reverse line blot assays underestimates the genetic heterogeneity among NTM. This heterogeneity can be clinically relevant because particular sub-groupings of species can cause specific disease types. Therefore, sequence-based identification is preferable, at least at the reference laboratory level, although the exact targets needed for clinically useful results remain to be established. The number of NTM species in the environment is probably so high that unidentifiable clinical isolates should be given a separate species status only if this is clinically meaningful.

show abstract

“…M. phlei was repeatedly isolated from synovial fluid and tissue in an immunocompetent pediatric patient with conjunctivitis, urethritis, and arthritis (1). Most of the existing identification methods for mycobacterial isolates rely on just a single genetic target, and often diverse variants are grouped in one (sub)species (11). Whole-genome sequencing provides the highest resolution on the DNA level and therefore is the most reliable approach for determining the genetic relatedness of mycobacteria.…”

mentioning

confidence: 99%